<DOC>
	<DOCNO>NCT02234518</DOCNO>
	<brief_summary>Gastrointestinal discomfort regularly affect &gt; 25 % population worldwide . One major contributor GI discomfort constipation , prevalence ~15 % symptom significant negative impact sufferer 's quality life . One hallmarks chronic constipation slow progression content gut ( i.e . slow gut / colonic transit time ) , may associate hard stool difficult expel . Dietary fiber supplement widely use first-line treatment constipation although little Level 1 evidence exists support use adult . The effectiveness different fiber supplement difficult compare give wide difference water-retention capability effect colonic microbial ecology . Given promising , yet largely unsubstantiated , benefit fiber supplementation symptom functional constipation , objective clinical trial evaluate tolerance effectiveness four week supplementation fiber product , dose-ranging fashion , whole gut transit time gastrointestinal symptom adult functional constipation .</brief_summary>
	<brief_title>Fibers Gut Health</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Men woman age 1875 ; female subject childbearing potential must willing use reliable method contraception throughout study period BMI : 18.5 29.9 kg/m2 Recruitment base simplify core ROME III diagnostic criterion functional constipation ( base specific screen question ) : ) . average Bristol stool type 1 4 AND frequency 1 3 spontaneous bowel movement ( SBMs ) per week b ) . plus least ONE : straining least 25 % defaecations ; sensation incomplete evacuation least 25 % defaecations ; sensation anorectal obstruction / blockage least 25 % defaecations ; use manual manoeuvre least 25 % defaecations Cleveland Clinic constipation score ( CCCS ) 820 Lowmoderate fiber intake ( â‰¤18g ) determine semiquantitative food intake screener know Block Fiber Screener Ability understand patient information sheet instruction Dutch , able provide inform consent Subjects report lactose intolerance and/or allergic soy cow milk protein Pregnant breastfeed woman Ongoing diagnosed gastrointestinal disease complication ( Crohn 's disease , Coeliac disease , chronic diarrhoea ) Any clinical relevant abnormality screen visit medical examination alarm feature sudden unintentional weight loss , rectal bleeding , recent change bowel habit ( &lt; 3 month ) , abdominal pain stool positive occult blood Prior abdominal surgery ( include gastric bypass laparoscopic banding ) , except cholecystectomy appendicectomy Neurologic diseases multiple sclerosis , stroke , spinal cord injury , Hirschsprung disease Chronic medication opinion investigator would impact gut motility Illness may preclude subject 's ability complete study may confound study outcome ( e.g . bowel cancer , prostate cancer , terminal illness , severe cardiovascular disease , chronic renal failure eat disorder ) serious illness result &gt; 2 week inability work 3 month study start Subjects comorbid illnesses cardiovascular , endocrine , renal chronic disease likely affect gut motility limit normal function ( e.g . reduced mobility increase fragility ) Ongoing alcohol , drug , medication abuse ( anamnesis ) Selfreported symptom pelvic organ prolapse Moderate severe active local anorectal problem recurrent anal fissure , bleeding , large prolapse haemorrhoid Regular use fiber supplementation ( e.g . Fybogel , Lactulose ) ( i.e . 1 standard dose ) week prior screen visit 6 standard dos past 1 month prior screen visit Participation another study investigational product within 3 month screen Investigator believe participant physically mentally unfit participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>